Abstract
Background: Ustekinumab is a fully human monoclonal antibody which binds Interleukin (IL)-12/23. It is indicated for the treatment of moderate-severe psoriasis and active psoriatic arthritis. Few data are available about the possibility of an interaction between ustekinumab and the liver.
Case Description: We reported a case of a 61-year old woman admitted to our Unit for severe transaminase elevation (aspartate transaminase 756 IU/l, alanine transaminase 1212 IU/l) occurred after a single Ustekinumab infusion for psoriasis. All other possible causes of liver damage, including drugs, hepatitis viruses, auto-antibodies and metabolic disorders were excluded. Liver biopsy showed lymphocytic infiltration, biliary duct damage and piecemeal necrosis. On the bases of the nonspecific histological picture and Rucam score, we accomplished the diagnosis of “liver injury of iatrogenic origin”. After drug withdrawal, a spontaneous normalization of liver enzymes occurred within six months.
Keywords: Ustekinumab, drug-induced liver injury, transaminase elevation, liver, adverse events, HBV, HCV.
Graphical Abstract
Current Drug Safety
Title:A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal
Volume: 13 Issue: 3
Author(s): Rosa Lovero, Giuseppe Losurdo, Marcella Mastromauro, Nicola Maurizio Castellaneta, Antonio Mongelli, Antonietta Gentile, Alfredo Di Leo and Mariabeatrice Principi*
Affiliation:
- Section of Gastroenterology, Department of Emergency and Organ Transplantation, AOU Policlinico, University of Bari, Bari,Italy
Keywords: Ustekinumab, drug-induced liver injury, transaminase elevation, liver, adverse events, HBV, HCV.
Abstract: Background: Ustekinumab is a fully human monoclonal antibody which binds Interleukin (IL)-12/23. It is indicated for the treatment of moderate-severe psoriasis and active psoriatic arthritis. Few data are available about the possibility of an interaction between ustekinumab and the liver.
Case Description: We reported a case of a 61-year old woman admitted to our Unit for severe transaminase elevation (aspartate transaminase 756 IU/l, alanine transaminase 1212 IU/l) occurred after a single Ustekinumab infusion for psoriasis. All other possible causes of liver damage, including drugs, hepatitis viruses, auto-antibodies and metabolic disorders were excluded. Liver biopsy showed lymphocytic infiltration, biliary duct damage and piecemeal necrosis. On the bases of the nonspecific histological picture and Rucam score, we accomplished the diagnosis of “liver injury of iatrogenic origin”. After drug withdrawal, a spontaneous normalization of liver enzymes occurred within six months.
Export Options
About this article
Cite this article as:
Lovero Rosa , Losurdo Giuseppe , Mastromauro Marcella , Castellaneta Maurizio Nicola , Mongelli Antonio , Gentile Antonietta , Di Leo Alfredo and Principi Mariabeatrice *, A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal, Current Drug Safety 2018; 13 (3) . https://dx.doi.org/10.2174/1574886313666180719165212
DOI https://dx.doi.org/10.2174/1574886313666180719165212 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effects of Lipid-Regulating Therapy on Haemostatic Parameters
Current Pharmaceutical Design Hepatocyte Growth Factor and Insulin-like Growth Factor-1 based Cellular Therapies for Oxidative Stress Injury
Current Stem Cell Research & Therapy Preclinical Studies of PROTACs in Hematological Malignancies
Cardiovascular & Hematological Disorders-Drug Targets Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design Mesenchymal Stem Cell Derived-Exosomes as Effective Factors in Reducing Cytokine Storm Symptoms of COVID-19
Protein & Peptide Letters Assessing the Gender Differences of Adverse Effects in HIV Infection Treatment Based on FDA AERS Database.
Current Bioinformatics SCF E3 Ubiquitin Ligases as Anticancer Targets
Current Cancer Drug Targets Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Dendritic Cells and Macrophages: Same Receptors but Different Functions
Current Immunology Reviews (Discontinued) Lectin Microarrays: A Powerful Tool for Glycan-Based Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Should We be Concerned About the Inflammatory Response to Endovascular Procedures?
Current Vascular Pharmacology Natural Killer T Cells as Targets for Therapeutic Intervention in Autoimmune Diseases
Current Pharmaceutical Design How to Keep Oxidative Stress Under Control?
Current Nutrition & Food Science Food Bioactives versus Drugs – Introduction
Current Pediatric Reviews Hematopoietic Colony Stimulating Factors in Cardiovascular and Pulmonary Remodeling: Promoters or Inhibitors?
Current Pharmaceutical Design Pharmaceutical Aspects of Hemoglobin-Based Oxygen Carriers
Current Drug Delivery Smoking and Endothelial Dysfunction
Current Vascular Pharmacology Editorial [Hot topic: Hepatocyte Growth Factor and cMET, New Development in Cancer Therapies (Guest Editors: T.A. Martin and W.G. Jiang)]
Anti-Cancer Agents in Medicinal Chemistry Interactions of Liposomes with Cells In Vitro and In Vivo: Opsonins and Receptors
Current Drug Metabolism Dietary Nutrients in Relation to Chronic Obstructive Pulmonary Disease: Emerging Epidemiological Evidence
Current Respiratory Medicine Reviews